PEP-Therapy is a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology based on the Company’s innovative Cell Penetrating and Interfering Peptides (CP&IP) technology. These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, leading to the inhibition of key pathological mechanisms without altering physiological mechanisms.
PEP-010, first CP&IP-based drug candidate, is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile.
PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors.
PEP-Therapy was founded in 2014 and builds on research results from Institut Curie and Sorbonne University. The company is backed by international investors.
PEP-010, first CP&IP-based drug candidate, is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile.
PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors.
PEP-Therapy was founded in 2014 and builds on research results from Institut Curie and Sorbonne University. The company is backed by international investors.
Location: France, Ile-de-France
Employees: 1-10
Total raised: $4.48M
Founded date: 2014
Investors 1
| Date | Name | Website |
| 22.03.2022 | Business A... | business-a... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 20.07.2021 | Series A | $3.06M | - |
| 27.04.2015 | - | $1.41M | - |
Mentions in press and media 5
| Date | Title | Description |
| 17.03.2025 | PEP-Therapy receives FDA Orphan Drug Designation for PEP-010 for treatment of Pancreatic Cancer | Press release PEP-Therapy receives FDA Orphan Drug Designation for PEP-010 for treatment of Pancreatic Cancer Paris (France), March 17, 2025 – PEP-Therapy, a clinical-stage biotechnology company developing first-in-class peptides as targete... |
| 25.04.2024 | PEP-Therapy et l’Institut Curie annoncent le traitement des premiers patients dans la phase Ib de l’essai clinique évaluant PEP-010 dans les cancers de l’ovaire et du pancréas | Communiqué de presse PEP-Therapy et l’Institut Curie annoncent le traitement des premiers patients dans la phase Ib de l’essai clinique évaluant PEP-010 dans les cancers de l’ovaire et du pancréas Paris (France), le 25 avril 2024 – PEP-Ther... |
| 25.04.2024 | PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers | Press release PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers Paris (France), April 25, 2024 – PEP-Therapy, a clinical-stage biotechnology company ... |
| 20.07.2021 | PEP-Therapy Raises €2.6M in Series A Extension Financing | PEP-Therapy, a Paris, France-based biotechnology company, raised an additional €2.6m ($3m) in an extension of its Series A financing round. The funding, which brought the total raised in the round to date to €5.4m ($6.4m) included €1.6m in ... |
| 27.04.2015 | PEP-Therapy Raises €1.3M in Funding | PEP-Therapy, a Paris, France-based biotechnology company developing targeted therapies for cancer treatments, raised €1.3m in funding. Backers included the Quadrivium 1 seed fund managed by Seventure Partners, for €1m, supplemented by a per... |